Survival and causes of death among veterans with lower extremity revascularization with paclitaxel-coated devices: Insights from the veterans health administration

Jorge Antonio Gutierrez, Sunil V. Rao, William Schuyler Jones, Eric A. Secemsky, Aaron W. Aday, Lin Gu, Ryan D. Schulteis, Mitchell W. Krucoff, Roseann White, Ehrin J. Armstrong, Subhash Banerjee, Shirling Tsai, Manesh R. Patel, Rajesh V. Swaminathan

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


BACKGROUND: The long-term safety of paclitaxel-coated devices (PCDs; drug-coated balloon or drug-eluting stent) for peripheral endovascular intervention is uncertain. We used data from the Veterans Health Administration to evaluate the association between PCDs, long-term mortality, and cause of death. METHODS AND RESULTS: Using the Veterans Administration Corporate Data Warehouse in conjunction with International Classification of Diseases, Tenth Revision (ICD-10) Procedure Coding System, Current Procedural Terminology, and Healthcare Common Procedure Coding System codes, we identified patients with peripheral artery disease treated within the Veterans Administration for femoropopliteal artery revascularization between October 1, 2015, and June 30, 2019. An adjusted Cox regression, using stabilized inverse probability–weighted estimates, was used to evaluate the association between PCDs and long-term survival. Cause of death data were obtained using the National Death Index. In total, 10 505 patients underwent femoropopliteal peripheral endovascular intervention; 2265 (21.6%) with a PCD and 8240 (78.4%) with a non-PCD (percutaneous angioplasty balloon and/or bare metal stent). Survival rates at 2 years (77.4% versus 79.7%) and 3 years (70.7% versus 71.8%) were similar between PCD and non-PCD groups, respectively. The adjusted hazard for all-cause mortality for patients treated with a PCD versus non-PCD was 1.06 (95% CI, 0.95–1.18, P=0.3013). Among patients who died between October 1, 2015, and December 31, 2017, the cause of death according to treatment group, PCD versus non-PCD, was similar. CONCLUSIONS: Among patients undergoing femoropopliteal peripheral endovascular intervention within the Veterans Administration Health Administration, there was no increased risk of long-term, all-cause mortality associated with PCD use. Cause-specific mortality rates were similar between treatment groups.

Original languageEnglish (US)
Article numbere018149
Pages (from-to)1-25
Number of pages25
JournalJournal of the American Heart Association
Issue number4
StatePublished - Feb 16 2021


  • Paclitaxel
  • Peripheral artery disease
  • Peripheral endovascular intervention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Survival and causes of death among veterans with lower extremity revascularization with paclitaxel-coated devices: Insights from the veterans health administration'. Together they form a unique fingerprint.

Cite this